The goal of this intervention trial is to evaluate whether combining meldonium therapy with PUFAs (polyunsaturated fatty acids) supplements containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) changes the plasma (blood component) concentration of EPA and DHA, as well as the acylcarnitine (fatty acid metabolite) profile in healthy volunteers. The main questions it aims to answer are: Does using meldonium together with PUFA supplements increase PUFA (EPA and DHA) concentrations in blood plasma? Does meldonium therapy change change the fatty acid metabolite (acylcarnitine) profile, if used together with PUFA supplements? Researchers compared plasma metabolic parameters in the beginning, middle and end of study period in a group who received only PUFA supplements, with a group which got PUFA supplements at the beginning, but after one month meldonium therapy was added and a group which got meldonium therapy at the beginning, but after one month PUFA supplements were added. Participants: 1. Received detailed information about the study and signed an informed consent form. 2. They were assigned to one of three study groups and received PUFAs and/or meldonium for the duration of the study. 3. Plasma samples were collected at the beginning, middle and end of the study period.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Changes in the plasma concentrations of EPA and DHA
Timeframe: From enrollment moment to the end of 8 week study period
Changes in plasma acetylcarnitine concentrations
Timeframe: From the enrollment moment to the end of 8 week study period
Changes in plasma medium-chain acylcarnitine concentration
Timeframe: From enrollment moment to the end of 8 week study period
Changes in plasma long-chain acylcarnitine concentration
Timeframe: Time Frame: From the enrollment moment to the end of 8 week study period